Nafazatrom: in-vitro assessment of radiation and drug activity against animal and human cell lines.
The B-16 melanoma animal cell line and HEC-1A human endometrial cell line treated with Nafazatrom (NFZ) (5 mu/ml) and varying doses of ionizing radiation show a dose response curve of increased colony inhibition with increasing radiation dose. The B-16 line consistently demonstrated enhanced colony inhibition when NFZ was added prior to radiation. This colony inhibition by NFZ was not seen in the HEC-1A cell line. No adverse effect, i.e., increased tumor colony growth, was evident when NFZ and radiation were combined. This study suggests that ionizing radiation can be combined with NFZ without adverse effect on the cell killing effects of either modality.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000818:Animals; D000970:Antineoplastic Agents; D002460:Cell Line; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000532:radiotherapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000532:radiotherapy; D011720:Pyrazoles / Q000494:pharmacology*; D047069:Pyrazolones; D014594:Uterine Neoplasms
D000970:Antineoplastic Agents; D011720:Pyrazoles; D047069:Pyrazolones; C018845:nafazatrom